DRI approaches $1bn target for Fund III

The pharmaceutical royalties-focused firm is expected to close Fund III above target after coming to market in mid-2012.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this